Title:
HAPTEN-CARRIER CONJUGATES WITH BACTERIAL TOXINS HAVING A SIGNAL PEPTIDE AS CARRIER AND THEIR USE IN IMMUNOGENIC COMPOSITIONS
Document Type and Number:
WIPO Patent Application WO/2010/103017
Kind Code:
A3
Abstract:
This invention relates to immunogenic compositions for inducing an immune response against an antigen of interest. In particular, the invention provides immunogenic compositions comprising an antigen-carrier conjugate, wherein the carrier is a bacterial toxin that contains a signal peptide. The invention also provides methods of generating immunogenic compositions with enhanced immunogenic ity, comprising adding a signal peptide to the bacterial carrier in an antigen-carrier conjugate, such as a hapten-carrier conjugate. The invention also provides methods for inducing an immune response to a hapten in a subject using these immunogenic compositions.
Inventors:
HENRY WILLIAM (GB)
Application Number:
PCT/EP2010/052997
Publication Date:
December 02, 2010
Filing Date:
March 09, 2010
Export Citation:
Assignee:
HENRY WILLIAM (GB)
International Classes:
A61K31/465; A61K47/48; A61K31/55; A61P37/02
Domestic Patent References:
| WO2005042749A1 | 2005-05-12 |
Foreign References:
| US5760184A | 1998-06-02 |
Other References:
KOSTEN T R ET AL: "Human therapeutic cocaine vaccine: safety and immunogenicity", VACCINE, ELSEVIER LTD, GB LNKD- DOI:10.1016/S0264-410X(01)00425-X, vol. 20, no. 7-8, 15 January 2002 (2002-01-15), pages 1196 - 1204, XP004332992, ISSN: 0264-410X
JERTBORN M ET AL: "Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers", VACCINE, ELSEVIER LTD, GB LNKD- DOI:10.1016/0264-410X(92)90030-N, vol. 10, no. 2, 1 January 1992 (1992-01-01), pages 130 - 132, XP023710419, ISSN: 0264-410X, [retrieved on 19920101]
XENOVA GROUP: "News release, Anti-Smoking Vaccine TA-NIC Preliminary 12 Month Clinical Trial Results", 3 March 2005 (2005-03-03), pages 1 - 4, XP002601885, Retrieved from the Internet [retrieved on 20100922]
EMEA: "Scientific Discussion, Dukoral", 1 January 2005 (2005-01-01), XP002601886, Retrieved from the Internet [retrieved on 20100922]
CERNY E H ET AL: "Preclinical development of a vaccine 'against smoking'.", ONKOLOGIE OCT 2002 LNKD- PUBMED:12415193, vol. 25, no. 5, October 2002 (2002-10-01), pages 406 - 411, XP008127230, ISSN: 0378-584X
HANEY M ET AL: "THERAPEUTIC VACCINES FOR SUBSTANCE DEPENDENCE", EXPERT REVIEW OF VACCINES, FUTURE DRUGS, LONDON, GB LNKD- DOI:10.1586/14760584.3.1.11, vol. 3, 1 January 2004 (2004-01-01), pages 11 - 18, XP008065788, ISSN: 1476-0584
JERTBORN M ET AL: "Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers", VACCINE, ELSEVIER LTD, GB LNKD- DOI:10.1016/0264-410X(92)90030-N, vol. 10, no. 2, 1 January 1992 (1992-01-01), pages 130 - 132, XP023710419, ISSN: 0264-410X, [retrieved on 19920101]
XENOVA GROUP: "News release, Anti-Smoking Vaccine TA-NIC Preliminary 12 Month Clinical Trial Results", 3 March 2005 (2005-03-03), pages 1 - 4, XP002601885, Retrieved from the Internet
EMEA: "Scientific Discussion, Dukoral", 1 January 2005 (2005-01-01), XP002601886, Retrieved from the Internet
CERNY E H ET AL: "Preclinical development of a vaccine 'against smoking'.", ONKOLOGIE OCT 2002 LNKD- PUBMED:12415193, vol. 25, no. 5, October 2002 (2002-10-01), pages 406 - 411, XP008127230, ISSN: 0378-584X
HANEY M ET AL: "THERAPEUTIC VACCINES FOR SUBSTANCE DEPENDENCE", EXPERT REVIEW OF VACCINES, FUTURE DRUGS, LONDON, GB LNKD- DOI:10.1586/14760584.3.1.11, vol. 3, 1 January 2004 (2004-01-01), pages 11 - 18, XP008065788, ISSN: 1476-0584
Attorney, Agent or Firm:
JONES DAY (München, DE)
Download PDF: